All In Biotech

Drug Trial Radar · NCT04706910

18F-DOPA II - PET Imaging Optimization

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jan 20, 2021

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
University of AlbertaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.

Conditions

  • Congenital Hyperinsulinism
  • Neuroblastoma
  • Parkinson Disease
  • Lewy Body Disease
  • Neuroendocrine Tumors
  • Brain Tumor

Interventions

  • 18F-DOPADrug

    All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study

  • Furosemide InjectionDrug

    Some participants will receive an intravenous injection of furosemide (40mg, single dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimum lesion detectibility (size)Time frame: Within 1 month of PET/CT scan
  2. Assessment of bladder activityTime frame: Within 1 month of PET/CT scan
  3. Assessment of bladder activity artifactTime frame: Within 1 month of PET/CT scan
  4. Minimum lesion detectability (SUV)Time frame: Within 1 month of PET/CT scan

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WC Mackenzie Health Science Centre / University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.